COVID-19 survivors may not need a second dose of mRNA-based vaccine to prevent subsequent symptomatic infections, which could stretch limited vaccine supplies, reports a research letter published yesterday in the New England Journal of Medicine.Researchers at the Icahn School of Medicine at Mount Sinai used a convenience sample from an ongoing study of 110 participants in the longitudinal Protection Associated with Rapid Immunity to SARS-CoV-2 (PARIS) study.
All received one dose of the Pfizer/BioNTech or Moderna vaccine in 2020, although 39.0% were seropositive for COVID-19 antibodies prior to vaccination.